Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. - Wikidata - awgldk - TriplyDB

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

http://www.wikidata.org/entity/Q36495076

about

Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents A review on segmentation of positron emission tomography images The potential roles of 18F-FDG-PET in management of acute stroke patients The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy Assessment of cardiac sarcoidosis with advanced imaging modalities Imaging biomarker roadmap for cancer studies Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT Validation of novel imaging methodologies for use as cancer clinical trial end-points Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sources PET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error.Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study.Longitudinal optical imaging of tumor metabolism and hemodynamics False Positive Positron Emission Tomography / Computed Tomography Scans in Treated Head and Neck Cancers.The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.F-18 FDG PET Images of the Cervix at Various Time Points after the Loop Electrosurgical Excision Procedure.Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors Isolated system towards a successful radiotherapy treatment.Methodological considerations in quantification of oncological FDG PET studies.Molecular imaging of metastatic potential.A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma.18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy.Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study.Variability in PET quantitation within a multicenter consortium.Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases.Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer.Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study.Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials.Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer

P2860

Q26740567-E23787C3-4B18-4223-86A3-DA2F8E5B20E4 Q26825470-64B3F2A0-2D21-47D7-BC5E-3CBD7F5A537D Q26827823-4AE4C3C2-A3E0-4220-9A53-1D269CFB55A2 Q26863624-F94B80B2-F5E3-4823-9BD2-2A713962A0A0 Q27024252-E900ABD4-2D84-4C0E-AD52-6AAE422E4C49 Q30242020-19782898-1C15-4BC9-B2DA-02D774D4346E Q30248546-8CA7EEEE-5917-409A-8525-CE3025EEC0D8 Q30465097-42C044FD-F187-486A-B874-4E8F9607BC46 Q30523931-18C62A6B-BD49-4D5E-A36F-0E9227DE3875 Q33394106-054B363E-BEC6-4A66-A9E2-9DC64CEDEA96 Q33407093-6E1AC4D0-EF8F-4E81-9036-4227ED661552 Q33413085-EA1D29D2-D7CE-4DAF-B724-58BD2BFF4CD3 Q33429801-D2ADC61C-ED23-4A74-A3DF-4EB993BC5070 Q33517098-B8E7C5C2-5BDE-404D-8FC8-A428EDAA2CC5 Q33517102-CC5ADE6F-42EF-49BA-B7BB-374F1B6CBB5E Q33631226-B50722F7-B1FE-4CD0-88AE-54F53FEC3543 Q33632108-26596252-EB90-4120-B2F9-14A34ABF6F4D Q33658264-6678EC49-030B-4425-9633-E70015350BAF Q33696003-0CE05155-F8BA-4DB0-8D4A-97D28F54FC7C Q33696408-B546D798-B4F5-459A-82E8-56F50FC1DEC2 Q33704250-01424654-0A51-48BD-95BC-ABCF11D39AEC Q33731220-A3CC1A5A-6159-4221-B367-66F101FCC259 Q33797361-18D7446C-203A-4715-A390-FCD76E5AADE0 Q33797380-F5AA8EAF-B15A-485F-9F99-E98DA68563F6 Q33806271-719ACB39-26F6-4512-BE53-4DAE0E9E8E69 Q33838696-A6FC60CC-4898-44E5-9ED0-D070E67888DD Q33915164-2C7CB972-4308-43AA-B4AC-A526500E5E72 Q33917943-87D62C39-DE38-4915-9745-5C5B6F925702 Q33952842-1E28F308-BB4B-4A30-934C-D80A7CA176C2 Q33973367-628BB76C-2663-4FC6-AC7E-53363A9CC739 Q33994603-FB315E71-7CDC-4B71-9600-CE579B6CFEAD Q34000970-1FC7E75C-E50C-4540-8A60-3150E8CBC555 Q34023973-31D9A78A-DE71-46C9-A4BF-A02CF4117A0C Q34047125-1A5C68D8-EF58-42B1-8EED-5E49A71E5D2B Q34075225-F0DC1C97-322D-4CB4-81C5-297C937160F5 Q34078246-3ACA5765-2373-42D9-99D8-2B60B5DA4E5F Q34093217-B27DE949-7684-4882-BEEC-DFFFD073941E Q34163791-19992F79-5340-472B-BB10-EBD785563E8A Q34175770-FE217BAF-D4B8-402E-A635-8E6DD59783F3 Q34243500-20113A89-C994-49FB-8525-5F9505D253D2

P2860

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

http://www.wikidata.org/entity/Q36495076

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Consensus recommendations for ...... ional Cancer Institute Trials.

@ast

Consensus recommendations for ...... ional Cancer Institute Trials.

@en

type

label

Consensus recommendations for ...... ional Cancer Institute Trials.

@ast

Consensus recommendations for ...... ional Cancer Institute Trials.

@en

prefLabel

Consensus recommendations for ...... ional Cancer Institute Trials.

@ast

Consensus recommendations for ...... ional Cancer Institute Trials.

@en

P1433

Q36495076-64BCAEF9-34C3-4D2A-96CC-72D8B0892513

P1476

Q36495076-9523A147-25B7-4930-806E-4C0119600E47

P2093

Q36495076-03CB996E-6D26-441C-85B6-7156F791597E

Q36495076-11337DEA-1BD2-46AF-818F-2763CA2101CF

Q36495076-21593DBE-BB4D-47CA-96CA-8AE199DB63E1

Q36495076-2D8A61A5-78B2-44AD-A4BA-E9963BAD9A68

Q36495076-587B043D-CE6F-49AA-BE34-CED46F2B7FBC

Q36495076-6487CD00-38C2-4E6B-A717-70AA0B4E2104

Q36495076-84B56494-66DB-4678-976C-54C805143E08

Q36495076-90D575EA-7494-4E7A-B8C3-EA1404620E6D

Q36495076-97E9F72F-6B4F-4C91-8426-83D94F2DD56E

Q36495076-A538A9F7-F030-4F6A-8973-BFDB1DEE2095

P304

Q36495076-EDE5B9CF-7404-4E93-B58D-B6116FAB15E8

P31

Q36495076-805B3D3B-D660-4B28-815B-090437133BE2

P407

Q36495076-02124CFB-3A8B-413D-A7FF-06687507DC55

P433

Q36495076-707D52F3-9CA9-4E7D-89E4-9AA7F28D0BCF

P478

Q36495076-4A935F6D-A813-4990-9144-0B3B6399A7AE

P50

Q36495076-505933A2-C242-495F-9D9D-8ABF18298D15

P577

Q36495076-1BD0A8DC-33ED-41E5-8237-C800B755DCC0

P698

Q36495076-655E561B-E8CC-4677-952C-AB75F0C9D2AA

P921

Q36495076-DE656726-B1CF-4350-859C-77C9328962CA

P1433

The Journal of Nuclear Medicine

P1476

Consensus recommendations for ...... tional Cancer Institute Trials

@en

P2093

Adriaan A Lammertsma

http://www.w3.org/2001/XMLSchema#string

Annick Van den Abbeele

http://www.w3.org/2001/XMLSchema#string

Barry A Siegel

http://www.w3.org/2001/XMLSchema#string

Daniel Sullivan

http://www.w3.org/2001/XMLSchema#string

David A Mankoff

http://www.w3.org/2001/XMLSchema#string

Joel Karp

http://www.w3.org/2001/XMLSchema#string

John M Hoffman

http://www.w3.org/2001/XMLSchema#string

Lalitha K Shankar

http://www.w3.org/2001/XMLSchema#string

Michael M Graham

http://www.w3.org/2001/XMLSchema#string

National Cancer Institute

http://www.w3.org/2001/XMLSchema#string

P304

1059-1066

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16741317

http://www.w3.org/2001/XMLSchema#string

P921